Skip to main content
    K

    Keros Therapeutics Inc (KROS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $10.03
    -0.27 (-2.62%)

    Market Cap: $202.13M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Keros Therapeutics Inc (KROS) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Keros Therapeutics (KROS) is expected to report earnings on Mar 2, 2027. In the quarter ended Sep 30, 2026, Keros Therapeutics reported EPS of $0.70, above the -$0.96 estimate. It beat the EPS estimate in 3 of the 8 most recent quarters that had an estimate.

    Earnings

    Performance (10Y)

    Beat Rate
    46%(12/26)
    Avg Surprise
    -20.80%
    Streak
    1 Q

    Upcoming Estimates

    Reports Mar 2, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$1.69
    Range-$2.43 - -$1.46
    9 analysts
    Revenue Consensus
    $437.14K
    RangeN/A
    9 analysts
    Reports May 12, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$1.51
    Range-$1.51 - -$1.51
    1 analysts
    EPS Revisions
    0
    2
    30d
    EPS Estimate DriftChange to current
    90d ago-$1.83+17.3%
    60d ago-$2.10+28.1%
    30d ago-$2.10+28.1%
    7d ago-$2.10+28.1%
    Current-$1.51
    Revenue Consensus
    N/A
    RangeN/A
    2 analysts

    Next Report

    KROS has an expected report date of Mar 2, 2027.

    Earnings History

    Of the 26 quarters below that had an estimate, KROS beat 12, missed 13 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $40.01M, up 180.6% from $14.26M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.70-$0.96-$1.53 - -$0.56+172.92%BeatN/A43 up, 1 downNov 5, 2026$40.01M
    Jun 30, 2026-$1.45-$1.25-$1.33 - -$1.20-16.00%MissN/A50 up, 4 downAug 3, 2026N/A
    Mar 31, 2026-$1.21-$0.73N/A-66.23%Miss-133.4%51 up, 3 downMay 14, 2026$367000
    Dec 31, 2025-$0.86-$0.45-$0.65 - -$0.16-91.11%MissN/A66 up, 0 downMar 4, 2026$385000
    Sep 30, 2025-$0.18-$1.11-$1.48 - -$0.26+83.78%BeatN/A80 up, 2 downNov 5, 2025$14.26M
    Jun 30, 2025-$0.76-$1.13-$1.30 - -$0.88+32.74%BeatN/A61 up, 2 downAug 6, 2025$18.17M
    Mar 31, 2025$3.62$0.01-$1.35 - $3.60N/AN/AN/A82 up, 0 downMay 6, 2025$211.25M
    Dec 31, 2024-$1.14-$0.43-$1.63 - $3.49-166.98%MissN/A100 up, 0 downFeb 26, 2025$3.04M
    Sep 30, 2024-$1.41-$1.28-$1.47 - -$1.11-10.16%MissN/A150 up, 1 downNov 6, 2024$388000
    Jun 30, 2024-$1.25-$1.25-$1.43 - -$1.100.00%In lineN/A100 up, 0 downAug 7, 2024$37000
    Mar 31, 2024-$1.21-$1.33-$1.62 - -$1.20+9.02%BeatN/A100 up, 0 downMay 8, 2024$83000
    Dec 31, 2023-$1.34-$1.37-$1.53 - -$1.22+2.19%BeatN/A110 up, 0 downFeb 28, 2024$143000
    Sep 30, 2023-$1.33-$1.35-$1.46 - -$1.27+1.48%BeatN/A90 up, 0 downNov 6, 2023$8000
    Jun 30, 2023-$1.27-$1.35-$1.43 - -$1.22+5.93%BeatN/A90 up, 0 downAug 7, 2023N/A
    Mar 31, 2023-$1.26-$1.14-$1.23 - -$1.05-10.53%MissN/A70 up, 0 downMay 4, 2023N/A
    Dec 31, 2022-$1.09-$1.10-$1.18 - -$0.99+0.91%BeatN/A70 up, 0 downMar 3, 2023N/A
    Sep 30, 2022-$0.92-$1.26-$1.32 - -$1.09+26.98%BeatN/A60 up, 0 downNov 3, 2022N/A
    Jun 30, 2022-$1.13-$1.07-$1.13 - -$1.00-5.61%MissN/A50 up, 0 downAug 4, 2022N/A
    Mar 31, 2022-$1.01-$0.86-$1.08 - -$0.34-17.44%MissN/A40 up, 0 downMay 5, 2022N/A
    Dec 31, 2021-$0.30-$0.92-$1.01 - -$0.87+67.39%BeatN/A40 up, 0 downMar 9, 2022$20.00M
    Sep 30, 2021-$0.87-$0.72-$0.81 - -$0.64-20.83%MissN/A41 up, 0 downNov 4, 2021N/A
    Jun 30, 2021-$0.67-$0.65-$0.76 - -$0.54-3.08%MissN/A4N/AAug 5, 2021$100000
    Mar 31, 2021-$0.68-$0.58-$0.65 - -$0.51-17.24%MissN/A4N/AMay 6, 2021N/A
    Dec 31, 2020-$0.49-$0.57-$0.62 - -$0.53+14.04%BeatN/A4N/AMar 25, 2021N/A
    Sep 30, 2020-$0.60-$0.59-$0.68 - -$0.50-1.69%MissN/A4N/ANov 10, 2020N/A
    Jun 30, 2020-$0.62-$0.67-$1.18 - -$0.49+7.46%BeatN/A4N/AAug 13, 2020N/A
    Mar 31, 2020-$5.11-$0.80N/A-538.75%MissN/AN/AN/AApr 8, 2020N/A
    Last 27 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $1.82, a profit after a loss of $5.01 per share the year before. It was -$6.82 for the year ended Dec 31, 2020, the oldest of the 6 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$1.82N/A
    Dec 31, 2024-$5.01N/A
    Dec 31, 2023-$5.20N/A
    Dec 31, 2022-$4.15N/A
    Dec 31, 2021-$2.52N/A
    Dec 31, 2020-$6.82N/A

    Frequently Asked Questions About KROS

    When is Keros Therapeutics's next earnings date?

    Keros Therapeutics's next earnings report is expected for Mar 2, 2027.

    Did KROS beat earnings estimates last quarter?

    Yes. Keros Therapeutics reported EPS of $0.70 for the quarter ended Sep 30, 2026, above the -$0.96 estimate, a 172.92% surprise.

    What EPS do analysts expect from KROS next quarter?

    The consensus EPS estimate for Keros Therapeutics for the quarter ending Dec 31, 2026 is -$1.69 from 9 analysts, with estimates from -$2.43 to -$1.46.

    How often does KROS beat earnings estimates?

    Keros Therapeutics beat the EPS estimate in 3 of the 8 most recent quarters that had an estimate, with an average surprise of -7.63%.